AC Immune has filed a patent for an antigenic peptide derived from amino acids 113-124 of alpha synuclein. The peptide has a specific structure and includes at least one mutation compared to the wild type sequence. It does not contain a specific dipeptide and can be used in treating synucleinopathies. GlobalData’s report on AC Immune gives a 360-degree view of the company including its patenting strategy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s company profile on AC Immune, Neuro-degenerative receptor binding drug compositions was a key innovation area identified from patents. AC Immune's grant share as of September 2023 was 34%. Grant share is based on the ratio of number of grants to total number of patents.
Antigenic peptide for treating synucleinopathies with specific amino acid structure
A recently filed patent (Publication Number: US20230287050A1) describes an antigenic peptide that may be used in the treatment or prevention of synucleinopathies, a group of neurodegenerative disorders that includes Parkinson's disease and Lewy body dementia. The antigenic peptide has a specific amino acid sequence and may have between 1 and 5 amino acid differences compared to a reference sequence. It may also have a terminal cysteine residue and be 11-20 amino acids in length. The patent also covers an immunogenic compound that includes the antigenic peptide and a carrier with T-cell epitopes, as well as a pharmaceutical preparation containing the antigenic peptide or immunogenic compound. The pharmaceutical preparation may further include an adjuvant and is formulated for parenteral administration. The patent also claims the use of the antigenic peptide, immunogenic compound, or pharmaceutical preparation for the treatment or prevention of synucleinopathies, including primary synucleinopathies like Parkinson's disease and Lewy body dementia, as well as concomitant pathologies like Alzheimer's disease and Huntington's disease. The patent also describes a method for administering the antigenic peptide, immunogenic compound, or pharmaceutical preparation to a subject in need of treatment. The use or method may be applicable to human subjects.
To know more about GlobalData’s detailed insights on AC Immune, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData Patent Analytics tracks bibliographic data, legal events data, point in time patent ownerships, and backward and forward citations from global patenting offices. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies
